A Prospective, Multicenter and Single-arm Target Value Clinical Study on the Efficacy and Safety of Peripheral Balloon Dilatation Catheter in PTA Procedure
| Registry | NCT01849601 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; non randomized, single group, masking: none, treatment |
| Enrollment | 167 (Actual) |
| Sponsor | Acotec Scientific Co., Ltd (Industry) |
| Conditions | Peripheral Arterial Disease |
| Interventions | percutaneous transluminal angioplasty balloon catheter (Device) |
| Dates | start 2012-12-01, primary completion 2013-03-01, completion 2013-03-01, first posted 2013-05-08, last updated 2015-03-23 |
| Locations | 1 site in China |
Related Papers Related Patents Related Grants Related Experts
All trials for Peripheral Arterial Disease All trials of percutaneous transluminal angioplasty balloon catheter
The purpose of this study is to determine whether the peripheral balloon dilatation catheter (trade name: Iris) is safe an effective in PTA procedure.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| PTA catheter | Experimental | Device: percutaneous transluminal angioplasty balloon catheter |
Sex: All, ages: 18 Years to 80 Years
Inclusion Criteria: * Age: 18 yrs - 80 yrs. * patients with iliac and / or femoral artery atherosclerotic lesions * Rutherford grade of 1-5; * Target lesion stenosis≥70% (visual estimation) (proportion of Trans-Atlantic Inter-Society Consensus(TASC) B, C and D grade lesions not less than 60% ) * Patients being able to understand the purpose of the test, and being volunteered to participate in and sign the informed consent. Exclusion Criteria: * Patients not suitable for receiving interventional surgeries of lower limb arteries for treatment; * Patients require intervention of lesions besides unilateral iliac and femoral artery lesions at the same time; * Patients have been involved in clinical trials of other drugs or medical devices within the past three months; * Patient is unable or unwilling to participate in this trial; * Patients with serious heart and brain, liver and other vital organs failure; * Patients with life expectancy less than 6 months; * Pregnant women.
| Facility | City | Country | Status |
|---|---|---|---|
| Wei Guo | Beijing | China |